Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer

International Journal of Cancer

Volumn 135, Issue 5, 2014, Pages 1142-1152

  Laban, Simon ^a   Atanackovic, Djordje ^a   Luetkens, Tim ^a   Knecht, Rainald ^a   Busch, Chia Jung ^a   Freytag, Marcus ^a   Spagnoli, Giulio ^b   Ritter, Gerd ^c   Hoffmann, Thomas K ^d   Knuth, Alexander ^e   Sauter, Guido ^a   Wilczak, Waldemar ^a   Blessmann, Marco ^a   Borgmann, Kerstin ^a   Muenscher, Adrian ^a   Clauditz, Till S ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

cancer testis antigens; head and neck squamous cell carcinoma (HNSCC); melanoma antigen (MAGE); NY ESO 1; tissue microarray (TMA)

Indexed keywords

CANCER TESTIS ANTIGEN; CYTOPLASM PROTEIN; MELANOMA ANTIGEN A; MELANOMA ANTIGEN C1; MELANOMA ANTIGEN C2; NUCLEAR PROTEIN; NY ESO 1 ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY;

CANCER-TESTIS ANTIGENS; HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC); MELANOMA ANTIGEN (MAGE); NY-ESO-1; TISSUE MICROARRAY (TMA);

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CYTOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MELANOMA-SPECIFIC ANTIGENS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84902536108     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28752     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Budach V, Cho C-H, Sedlmaier B, et al. Five years' results of the German ARO 04-01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. ASCO Meeting Abstracts 2012; 30: 5512.
3. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.
4. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2012; 26: 26.
5. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-15.
6. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704.
7. Tong CC, Kao J, Sikora AG,. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res 2012; 54: 266-74.
8. Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12: 465-72.
9. Wolf GT, Hudson JL, Peterson KA, et al. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986; 95: 142-52.
10. Chen YT, Gure AO, Tsang S, et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998; 95: 6919-23.
11. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
12. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
13. Caballero OL, Chen YT,. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-21.
14. van den Broek M, von Boehmer L, Knuth A,. Developments in cancer immunotherapy. Dig Dis 2010; 28: 51-6.
15. Atanackovic D, Blum I, Cao Y, et al. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther 2006; 5: 1218-25.
16. Cuffel C, Rivals JP, Zaugg Y, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer 2011; 128: 2625-34.
17. Figueiredo DL, Mamede RC, Proto-Siqueira R, et al. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 2006; 28: 614-9.
18. Figueiredo DL, Mamede RC, Spagnoli GC, et al. High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck 2011; 33: 702-7.
19. Montoro JR, Mamede RC, Neder Serafini L, et al. Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma. Head Neck 2012.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
21. Luetkens T, Schafhausen P, Uhlich F, et al. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res 2010; 34: 1647-55.
22. Simon R, Mirlacher M, Sauter G,. Immunohistochemical analysis of tissue microarrays. Methods Mol Biol 2010; 664: 113-26.
23. Clauditz TS, Wang CJ, Gontarewicz A, et al. Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2013; 42: 125-32.
24. Minner S, Kraetzig F, Tachezy M, et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol 2011; 42: 1946-52.
25. Hudolin T, Kastelan Z, Ilic I, et al. Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. J Trans Med 2013; 11: 123.
26. Balafoutas D, zur Hausen A, Mayer S, et al. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer 2013; 13: 271.
27. Perez D, Herrmann T, Jungbluth AA, et al. Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence. Int J Cancer 2008; 123: 1551-5.
28. Tinguely M, Jenni B, Knights A, et al. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci 2008; 99: 720-5.
29. Xu H, Gu N, Liu ZB, et al. NY-ESO-1 expression in hepatocellular carcinoma: a potential new marker for early recurrence after surgery. Oncol Lett 2012; 3: 39-44.
30. Cogdill AP, Frederick DT, Cooper ZA, et al. Targeting the MAGE A3 antigen in pancreatic cancer. Surgery 2012; 152: S13-8.
31. Dyrskjot L, Zieger K, Kissow Lildal T, et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer 2012; 107: 116-22.
32. Chen YT, Ross DS, Chiu R, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 2011; 6: e17876.
33. Matkovic B, Juretic A, Spagnoli GC, et al. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study. Croat Med J 2011; 52: 171-7.
34. Sharma P, Shen Y, Wen S, et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006; 12: 5442-7.
35. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-62.
36. Atanackovic D, Hildebrandt Y, Jadczak A, et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010; 95: 785-93.
37. Nardiello T, Jungbluth AA, Mei A, et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res 2011; 17: 4309-19.
38. Por E, Byun HJ, Lee EJ, et al. The cancer/testis antigen CAGE with oncogenic potential stimulates cell proliferation by up-regulating cyclins D1 and E in an AP-1- and E2F-dependent manner. J Biol Chem 2010; 285: 14475-85.
39. Cappell KM, Sinnott R, Taus P, et al. Multiple cancer testis antigens function to support tumor cell mitotic fidelity. Mol Cell Biol 2012; 32: 4131-40.
40. Peche LY, Scolz M, Ladelfa MF, et al. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ 2012; 19: 926-36.
41. Marcar L, Maclaine NJ, Hupp TR, et al. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 2010; 70: 10362-70.
42. Doyle JM, Gao J, Wang J, et al. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell 2010; 39: 963-74.
43. Bhatia N, Xiao TZ, Rosenthal KA, et al. MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. J Invest Dermatol 2013; 133: 759-67.
44. Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase ii randomized study results. J Clin Oncol 2013; 31: 2396-403.
45. Russo V, Pilla L, Lunghi F, et al. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer 2013; 132: 2557-66.